Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ovarian Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 51 articles:
HTML format



Single Articles


    September 2022
  1. GREEN DS, Ning F, Duemler A, Myers TG, et al
    Intraperitoneal monocytes and interferons as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results of a phase I clinical trial.
    Clin Cancer Res. 2022 Sep 13. pii: 709187. doi: 10.1158/1078-0432.CCR-22-1893.
    PubMed     Abstract available


  2. LHEUREUX S
    Multi-omics uncovering different faces of Clear Cell Ovarian Cancer.
    Clin Cancer Res. 2022 Sep 12. pii: 709169. doi: 10.1158/1078-0432.CCR-22-2365.
    PubMed     Abstract available


    August 2022
  3. IRAJIZAD E, Han CY, Celestino J, Wu R, et al
    A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses.
    Clin Cancer Res. 2022 Aug 29. pii: 708818. doi: 10.1158/1078-0432.CCR-22-1113.
    PubMed     Abstract available


  4. WIMBERGER P, Gerber MJ, Pfisterer J, Erdmann K, et al
    Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an anti-angiogenic VEGF-A splice variant.
    Clin Cancer Res. 2022 Aug 24. pii: 708584. doi: 10.1158/1078-0432.CCR-22-1326.
    PubMed     Abstract available


  5. BANERJEE S, Michalarea V, Ang JE, Ingles Garces A, et al
    A phase I trial of CT900, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer.
    Clin Cancer Res. 2022 Aug 19. pii: 708154. doi: 10.1158/1078-0432.CCR-22-1268.
    PubMed     Abstract available


  6. SERRA V, Wang AT, Castroviejo-Bermejo M, Polanska UM, et al
    Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.
    Clin Cancer Res. 2022 Aug 3. pii: 707431. doi: 10.1158/1078-0432.CCR-22-0568.
    PubMed     Abstract available


  7. LEE JM, Moore RG, Ghamande S, Park MS, et al
    Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
    Clin Cancer Res. 2022 Aug 2. pii: 707411. doi: 10.1158/1078-0432.CCR-21-1733.
    PubMed     Abstract available


    July 2022
  8. FISHER NC, Byrne RM, Leslie H, Wood C, et al
    Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data.
    Clin Cancer Res. 2022 Jul 6. pii: 706888. doi: 10.1158/1078-0432.CCR-22-1102.
    PubMed     Abstract available


    June 2022
  9. JOHNSON M, Dudek AZ, Sukari A, Call J, et al
    ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
    Clin Cancer Res. 2022;28:2517-2526.
    PubMed     Abstract available


  10. HOLLIS RL, Meynert AM, Michie CO, Rye T, et al
    Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification.
    Clin Cancer Res. 2022 Jun 13. pii: 704888. doi: 10.1158/1078-0432.CCR-22-0368.
    PubMed     Abstract available


  11. XU J, Fang Y, Chen K, Li S, et al
    Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer.
    Clin Cancer Res. 2022 Jun 8. pii: 704811. doi: 10.1158/1078-0432.CCR-22-0296.
    PubMed     Abstract available


  12. BYCHKOVSKY BL, Li T, Sotelo J, Tayob N, et al
    Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    Clin Cancer Res. 2022;28:2349-2360.
    PubMed     Abstract available


  13. NICUM S, Blagden SP
    PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    Clin Cancer Res. 2022;28:2201-2203.
    PubMed     Abstract available


    May 2022
  14. ARANDA F, Eguren-Santamaria I, Bella A, Berraondo P, et al
    Revisiting Intracavitary Immunotherapy of Cancer.
    Clin Cancer Res. 2022;28:1993-1995.
    PubMed     Abstract available


  15. FUCIKOVA J, Hensler M, Kasikova L, Lanickova T, et al
    An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors.
    Clin Cancer Res. 2022 May 10. pii: 696491. doi: 10.1158/1078-0432.CCR-21-4413.
    PubMed     Abstract available


    April 2022
  16. YANG SYC, Pugh TJ, Oza AM
    Double trouble: whole genome doubling distinguishes early from late ovarian cancer.
    Clin Cancer Res. 2022 Apr 27. pii: 694785. doi: 10.1158/1078-0432.CCR-22-0336.
    PubMed     Abstract available


  17. LIU M, Tayob N, Penter L, Sellars M, et al
    Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer.
    Clin Cancer Res. 2022 Apr 20. pii: 694633. doi: 10.1158/1078-0432.CCR-21-2834.
    PubMed     Abstract available


  18. CHENG Z, Mirza H, Ennis DP, Smith P, et al
    The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2022 Apr 10:OF1-OF12. doi: 10.1158/1078-0432.CCR-21-1643.
    PubMed     Abstract available


  19. AREND RC, Scalise CB, Gordon ER, Davis AM, et al
    Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.
    Clin Cancer Res. 2022;28:1433-1445.
    PubMed     Abstract available


    February 2022
  20. DIGKLIA A, Coukos G, Homicsko K
    Trabectedin and Durvalumab Combination is Feasible - and Active in Relapsing Ovarian Cancer.
    Clin Cancer Res. 2022 Feb 17. pii: 681578. doi: 10.1158/1078-0432.CCR-21-4592.
    PubMed     Abstract available


  21. GAO Q, Zhu J, Zhao W, Huang Y, et al
    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
    Clin Cancer Res. 2022 Feb 7. pii: 1078-0432.CCR-21-3023.
    PubMed     Abstract available


    January 2022
  22. ORR B, Mahdi H, Fang Y, Strange M, et al
    Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3659.
    PubMed     Abstract available


  23. VOUGIOUKLAKIS T, Zhu K, Vasudevaraja V, Serrano J, et al
    Integrated analysis of ovarian juvenile granulosa cell tumors reveals distinct epigenetic signatures and recurrent TERT rearrangements.
    Clin Cancer Res. 2022 Jan 14. pii: 1078-0432.CCR-21-3394.
    PubMed     Abstract available


    December 2021
  24. TOULMONDE M, Brahmi M, Giraud A, Chakiba C, et al
    Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2258.
    PubMed     Abstract available


  25. SHARMA SK, Mack KN, Piersigilli A, Pourat J, et al
    ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-1798.
    PubMed     Abstract available


    November 2021
  26. WU X, Zhu J, Wang J, Lin ZQ, et al
    Pamiparib Monotherapy for Patients With Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-1186.
    PubMed     Abstract available


  27. VAN DER WIJNGAART H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, et al
    Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
    Clin Cancer Res. 2021;27:6106-6114.
    PubMed     Abstract available


    October 2021
  28. TIAN L, Xu B, Teng KY, Song M, et al
    Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1248.
    PubMed     Abstract available


  29. MOORE KN, Chambers SK, Hamilton EP, Chen LM, et al
    Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-0158.
    PubMed     Abstract available


    September 2021
  30. SCHOUTEN PC, Richters LK, Vis DJ, Kommoss S, et al
    Ovarian cancer specific BRCA-like copy number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1673.
    PubMed     Abstract available


  31. CECIL DL, Liao JB, Dang Y, Coveler AL, et al
    Immunization with a plasmid DNA vaccine encoding the N-terminus of Insulin like Growth Factor Binding Protein-2 in advanced ovarian cancer leads to high level Type I immune responses.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-21-1579.
    PubMed     Abstract available


  32. WESTIN SN, Labrie M, Litton JK, Blucher A, et al
    Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-1656.
    PubMed     Abstract available


  33. DO KT, Kochupurakkal B, Kelland S, de Jonge A, et al
    Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
    Clin Cancer Res. 2021;27:4710-4716.
    PubMed     Abstract available


    August 2021
  34. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    PubMed     Abstract available


  35. SZTUPINSZKI Z, Diossy M, Borcsok J, Prosz A, et al
    Comparative Assessment of Diagnostic Homologous Recombination Deficiency associated mutational signatures in ovarian cancer.
    Clin Cancer Res. 2021 Aug 11. pii: 1078-0432.CCR-21-0981.
    PubMed     Abstract available


  36. KAMAT AA, Fletcher M, Gruman LM, Mueller P, et al
    Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.
    Clin Cancer Res. 2021;27:4455.
    PubMed    


    July 2021
  37. THAKER PH, Bradley WH, Leath CA, Gunderson Jackson C, et al
    GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-Escalation Study.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0360.
    PubMed     Abstract available


    May 2021
  38. KANDIMALLA R, Wang W, Yu F, Zhou N, et al
    OCaMIR - A noninvasive, diagnostic signature for early stage ovarian cancer: a multi-cohort retrospective and prospective study.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0267.
    PubMed     Abstract available


  39. MIAO YR, Thakkar KN, Qian J, Kariolis MS, et al
    Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
    Clin Cancer Res. 2021 May 19. pii: 1078-0432.CCR-20-0482.
    PubMed     Abstract available


  40. LAUMONT CM, Wouters MCA, Smazynski J, Gierc NS, et al
    Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes co-expressing CD39, CD103, and PD-1 in ovarian cancer.
    Clin Cancer Res. 2021 May 7. pii: 1078-0432.CCR-20-4394.
    PubMed     Abstract available


    March 2021
  41. THIBODEAUX S, Barnett B, Pandeswara S, Wall S, et al
    Interferon-alpha augments clinical efficacy of regulatory T cell depletion with denileukin diftitox in ovarian cancer.
    Clin Cancer Res. 2021 Mar 26. pii: 1078-0432.CCR-20-4594.
    PubMed     Abstract available


  42. KAZMI F, Nicum S, Roux RL, Spiers L, et al
    A Phase IB open-label, dose-escalation study of NUC1031 in combination with carboplatin for recurrent ovarian cancer.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4403.
    PubMed     Abstract available


  43. EWING A, Meynert A, Churchman M, Grimes G, et al
    Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4068.
    PubMed     Abstract available


    February 2021
  44. LI N, Bu H, Liu J, Zhu J, et al
    An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-3546.
    PubMed     Abstract available


    January 2021
  45. HONG B, Chapa V, Saini U, Modgil P, et al
    Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
    Clin Cancer Res. 2021;27:542-553.
    PubMed     Abstract available


  46. HU Z, Cunnea P, Zhong Z, Lu H, et al
    The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers.
    Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-2782.
    PubMed     Abstract available


    December 2020
  47. PARACCHINI L, Beltrame L, Grassi T, Inglesi A, et al
    Genome-wide copy number alterations in circulating tumor DNA as a novel biomarker in high grade serous ovarian cancer patients.
    Clin Cancer Res. 2020 Dec 15. pii: 1078-0432.CCR-20-3345.
    PubMed     Abstract available


    September 2020
  48. ISHAK CA, De Carvalho DD
    DNA methylation profiling of premalignant lesions as a path to ovarian cancer early detection.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-3331.
    PubMed     Abstract available


    December 2019
  49. LI F, Zhang Z, Cai J, Chen X, et al
    Primary preclinical and clinical Evaluation of 68Ga-DOTA-TMVP1 as a novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer.
    Clin Cancer Res. 2019 Dec 16. pii: 1078-0432.CCR-19-1845.
    PubMed     Abstract available


    October 2019
  50. SOLIMAN PT, Westin SN, Iglesias DA, Fellman BM, et al
    Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study.
    Clin Cancer Res. 2019 Oct 18. pii: 1078-0432.CCR-19-0471.
    PubMed     Abstract available


  51. MCCLOSKEY CW, Cook DP, Kelly BS, Azzi F, et al
    Metformin abrogates age-associated ovarian fibrosis.
    Clin Cancer Res. 2019 Oct 9. pii: 1078-0432.CCR-19-0603.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: